Orchard Therapeutics and SIRION Biotech Announce Licensing Agreement
Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, and SIRION Biotech GmbH announced the entry into a license agreement, pursuant to which Orchard has licensed SIRION’s LentiBOOST technology to enhance manufacturing efficiency for certain of Orchard’s ex vivo …
Orchard Therapeutics (NASDAQ:ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, and SIRION Biotech GmbH announced the entry into a license agreement, pursuant to which Orchard has licensed SIRION’s LentiBOOST technology to enhance manufacturing efficiency for certain of Orchard’s ex vivo autologous hematopoietic stem cell gene therapy drug candidates.
As quoted in the press release:
“At Orchard Therapeutics, we are establishing manufacturing capabilities to deliver potentially transformative gene therapy products to rare disease patients around the globe. Optimization of lentiviral transduction through a technology such as LentiBOOST™, along with the build-out of our recently announced manufacturing facility, are representative of our continued efforts to increase efficiencies and further streamline our approach to manufacturing gene therapy candidates,” said Stewart Craig, Ph.D., chief manufacturing officer of Orchard. “Current studies using LentiBOOST™ in our laboratories have resulted in encouraging data, and we look forward to examining the impact on our portfolio of gene therapy product candidates.”
Under the terms of the agreement, SIRION will provide Orchard with a license to its proprietary lentiviral transduction enhancer LentiBOOST™ for development and commercialization activities for select Orchard programs. SIRION will be entitled to upfront and milestone payments and is eligible to receive royalties on net sales of future products that utilize the LentiBOOST™ technology.
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1816.14 | -2.43 | |
Silver | 20.75 | -0.07 | |
Copper | 3.78 | 0.00 | |
Palladium | 1963.00 | +94.00 | |
Platinum | 916.00 | +6.00 | |
Oil | 111.12 | -0.64 | |
Heating Oil | 4.03 | -0.09 | |
Natural Gas | 6.54 | -0.03 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Featured stocks
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.